top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hBCMA MC38
Common name
B-hBCMA MC38 Catalog number    310720
Aliases

BCM, BCMA, CD269, TNFRSF13A

Disease  Colon carcinoma
Organism
Mouse 
Strain  C57BL/6
Tissue types Colon Tissue  Colon
Description

  • Origin: The MC38 cell line is derived from C57BL/6 murine colon adenocarcinoma cells. The cell line is a commonly used murine model for colorectal carcinoma.
  • Background Information: BCMA, also known as TNFRSF17, plays a major role in the maturation and differentiation of B cells into plasma cells. Under physiological conditions, BCMA is mainly expressed on plasma cell precursors and terminally differentiated plasma cells. In pathological situations, BCMA is expressed in almost all cases of multiple myeloma (MM), making it one of the star targets for MM drug development. Various BCMA-targeted drugs including antibody-drug conjugates (ADCs), chimeric antigen receptor T-cell therapies (CAR-T) and bispecific T-cell engagers (BiTEs) are currently under active clinical development.
  • Gene targeting strategy: The exogenous promoter and human BCMA coding sequence were inserted into the mouse ROSA26 locus of wild MC38 cell lines.
  • Tumorigenicity: Confirmed in C57BL/6 mice, B-h4-1BB mice, B-hCD3E mice.
  • Application: The B-hBCMA MC38 tumor models can be used for preclinical evaluation of monoclonal antibody drugs and bispecific antibody drugs targeting human BCMA.
  • Notes: 
  1. B-hBCMA MC38 cell line contains G418 resistance gene. After the cells have grown stably, 1000μg/mL of G418 needs to be added to maintain cell growth.
  2. It is recommended to choose anti-human BCMA antibodies with good specificity for protein expression analysis, such as Belantamab analog.

Targeting strategy


Gene targeting strategy for B-hBCMA MC38 cells. The exogenous promoter and human BCMA coding sequence were inserted into the mouse ROSA26 locus of wild MC38 cell lines.

Protein expression analysis 

from clipboard


BCMA expression analysis in B-hBCMA MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hBCMA MC38 cultures were stained with species-specific anti-BCMA antibody A (provide a client) and Belantamab analog (in house). Human BCMA was detected on the surface of B-hBCMA MC38 cells but not wild-type MC38 cells. The 2-B01 clone of B-hBCMA MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

from clipboard


Subcutaneous homograft tumor growth of B-hBCMA MC38 cells. B-hBCMA MC38 cells (5x105) and wild-type MC38 cells (5x105) were subcutaneously implanted into C57BL/6 mice (female, 5-8-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hBCMA MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

from clipboard


BCMA expression evaluated on B-hBCMA MC38 tumor cells by flow cytometry. B-hBCMA MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=5), and on 36 days post inoculation, tumor cells were harvested and assessed for human BCMA expression by flow cytometry using anti-human BCMA antibody A (provide a client). As shown, human BCMA was expressed on the surface of tumor cells. Therefore, B-hBCMA MC38 cells can be used for in vivo efficacy studies of novel BCMA therapeutics.

Tumor growth curve & Body weight changes

from clipboard


Subcutaneous homograft tumor growth of B-hBCMA MC38 cells. B-hBCMA MC38 cells (5x105, 5x106) and wild-type MC38 cells (5x105) were subcutaneously implanted into B-h4-1BB mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B)  Body weight. Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hBCMA MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.

Tumor growth curve & body weight changes

from clipboard



Subcutaneous tumor growth of B-hBCMA MC38 cells. B-hBCMA MC38 cells (5x106) and wild-type MC38 cells (5x105) were subcutaneously implanted into B-hCD3E mice (female, 6-8-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. Results indicate that B-hBCMA MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM. 


Protein expression analysis of tumor tissue


from clipboard


BCMA expression evaluated on B-hBCMA MC38 tumor cells by flow cytometry. B-hBCMA MC38 cells were subcutaneously transplanted into B-hCD3E mice (n=6). Upon conclusion of the experiment, tumor cells were harvested and assessed for human BCMA expression by flow cytometry using anti-human BCMA antibody Belantamab analog (in house). As shown, human BCMA was highly expressed on the surface of tumor cells. Therefore, B-hBCMA MC38 cells can be used for in vivo efficacy studies evaluating novel BCMA therapeutics.